Genmab — Oktober 2024
-
Well,
that is not completely true @Journalisten ; there have been enough rumours over the years for Jan to make public statements about it, that he wanted to stay independent and that the best way to do that would be to keep the share price as high as possible. He did that more then once. -
and the rumours were not without base. JNJ had a very sizable share position in Genmab already at the time. And looking back, if JNJ had chosen for a take-over instead of selling that position they would have made an amazing deal if you put it against all the royalties they are paying now
-
Det afhænger nok af, hvordan man definerer seriøse rygter. Der har været mange rygter samt analytikere, der har argumenteret for mulige opkøb, men indtil videre har der ikke været noget konkret bud. Vi ved ikke, hvad der er foregået bag lukkede døre, men det ser ud til, at Jan har afvist flere tilbud, da han gentagne gange har understreget, at Genmab ikke er til salg.
-
-
Hvis det var åbentlyst at Genmab var værdisat for højt for et år tid siden så ville der vel være kommet shortere i aktien. På et år har Genmab tabt 35% og NBI er steget 20% Patentudløb på dara er kun rykket et år tættere på i den tid. Synes nok det er svært at give en logisk forklaring på at vi pt er i 1550.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind